Author of the publication

Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.

, , , , , , , , , and . Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, (January 2017)
DOI: 10.1016/j.jchromb.2016.12.004

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates., , , , , , , , , and . Molecular therapy. Methods & clinical development, (September 2017)New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties, , , , , , , , , and 2 other author(s). Immunobiology, 218 (4): 496--505 (April 2013)Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters., , , , , and . Immunobiology, 220 (4): 476--482 (April 2015)Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3., , , , , , , , , and 1 other author(s). J.Clin.Periodontol., 43 (3): 238--249 (March 2016)Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS., , , , , , , , , and . Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, (January 2017)Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria., , , , , , , , , and 7 other author(s). 123 (13): 2094--2101 (March 2014)